Moral Injury and Practicing Oncology During COVID-19

Practicing oncology during COVID-19 was not simply “hard.” Hard is a long clinic day, a prior authorization form that seems to have been written by a raccoon with a law degree, or a tumor board that runs through lunch. The pandemic was different. It pushed cancer clinicians into situations where every decision seemed to carry a moral bruise: delay chemotherapy to reduce infection risk, or treat now and risk exposing an immunocompromised patient to a dangerous virus? Limit family presence at the bedside, or allow a dying patient the human comfort that medicine exists to protect? Choose scarce staff, rooms, masks, time, or infusion slotsthen go home wondering whether “the best available choice” was still the wrong one.

That is where moral injury in oncology enters the conversation. Moral injury occurs when clinicians witness, participate in, or feel unable to prevent actions that violate their deeply held professional values. During the COVID-19 pandemic, oncologists, oncology nurses, radiation therapists, surgeons, pharmacists, social workers, and palliative care teams were asked to deliver compassionate cancer care inside a crisis that often made compassion logistically difficult. The result was not ordinary stress. It was a collision between duty and reality.

This article explores how moral injury shaped the experience of practicing oncology during COVID-19, why cancer care was uniquely vulnerable, what it looked like in daily practice, and how oncology teams can heal without pretending the pandemic was merely a “learning opportunity” wrapped in N95 elastic.

What Is Moral Injury in Health Care?

Moral injury is not the same as burnout, although the two often shake hands in the hallway. Burnout is commonly linked to chronic workplace stress: too much work, too little control, poor support, emotional exhaustion, and the slow feeling that your professional battery has been replaced with a potato. Moral injury goes deeper. It involves a sense of ethical violation: “I could not give the care I believed my patient deserved,” or “The system forced me to act against my values.”

In oncology, values are not abstract. They are lived in exam rooms, infusion centers, operating suites, radiation vaults, and late-night phone calls. Cancer professionals are trained to weigh benefit and harm, respect patient goals, preserve dignity, communicate honestly, and keep showing up even when cure is not possible. COVID-19 strained each of those commitments.

Moral Distress vs. Moral Injury

Moral distress is the immediate pain of knowing the ethically appropriate action but being unable to take it because of institutional, legal, resource, or public health constraints. Moral injury is what can happen when those experiences accumulate or cut deeply enough to alter a clinician’s sense of self, trust, purpose, or safety.

For example, an oncologist may feel moral distress when a needed operation is postponed because the hospital has no intensive care capacity. Moral injury may develop when that oncologist later learns the cancer progressed during the delay and begins to think, “I failed this person,” even though the decision was made under crisis conditions.

Why COVID-19 Hit Oncology So Hard

Cancer care depends on timing. A suspicious mass cannot wait politely until the world calms down. A curative chemotherapy plan does not become less urgent because a virus is trending. Yet the early pandemic forced hospitals and clinics to reduce in-person visits, delay screenings, postpone elective procedures, shift to telemedicine, conserve personal protective equipment, and protect patients at higher risk of severe infection.

Patients with cancer often faced a double threat. On one side was the risk of COVID-19, especially for people receiving immunosuppressive therapy or living with blood cancers. On the other side was the risk of delayed diagnosis or treatment. Oncology teams had to keep both dangers in view, like trying to drive through fog while someone in the back seat reads lab results aloud.

The Impossible Math of Cancer Treatment Delays

During the pandemic, many cancer screenings and diagnostic procedures fell sharply. Mammograms, colonoscopies, biopsies, imaging studies, surgical consults, and routine follow-ups were interrupted in many communities. Some patients avoided hospitals because they feared infection. Others could not access appointments because services were paused, transportation was disrupted, or caregivers were unavailable.

For clinicians, this created a painful ethical calculation. Delaying treatment might reduce immediate infection exposure, but cancer biology does not pause for public health announcements. Continuing treatment might preserve cancer outcomes, but it could also expose a vulnerable patient to SARS-CoV-2. There was no perfect answer, only risk layered on risk.

The Main Sources of Moral Injury for Oncology Clinicians During COVID-19

1. Protecting Patients While Potentially Endangering Them

Oncology clinicians are accustomed to explaining risk. Chemotherapy has risks. Radiation has risks. Surgery has risks. But during COVID-19, even walking into the clinic carried a new kind of fear. A patient coming for life-prolonging treatment might be exposed in the waiting room, elevator, infusion chair, or hospital bed.

Clinicians had to ask: Is today’s treatment worth today’s infection risk? In many cases, yes. In others, maybe. In some, no. That uncertainty was ethically exhausting. It felt like practicing medicine while the floor kept changing its mind about being a floor.

2. Changing Treatment Plans Under Crisis Conditions

Some regimens were modified to reduce clinic visits. Oral therapies were favored when appropriate. Treatment intervals were stretched. Surgeries were postponed. Radiation schedules were adjusted. Telehealth replaced in-person visits for selected consultations and follow-ups.

Many of these changes were clinically reasonable. Some were even overdue innovations. But when the reason for change was not purely patient preference or best evidence, but pandemic scarcity, clinicians could feel complicit in a lower standard of careeven when they were making the best decision available.

3. Visitor Restrictions and Lonely Goodbyes

Few experiences left deeper marks than visitor restrictions. Oncology is an intensely human specialty. Families hear diagnoses together. They help patients remember medication schedules, absorb prognosis, ask the question the patient is too stunned to ask, and sit quietly when words fail.

During COVID-19 surges, many hospitals restricted visitors to reduce transmission. Clinicians understood the logic. They also saw the cost. Patients received bad news alone. Families joined by speakerphone. Some patients died with staff members as their only physical witnesses. For oncology teams, whose work often centers on dignity at the edge of life, this was morally devastating.

4. Scarcity of Staff, Space, and Protective Equipment

In the early pandemic, personal protective equipment was not always reliably available. Clinics redesigned workflows overnight. Staff shortages hit hard as clinicians became ill, quarantined, burned out, or left the workforce. Infusion centers had to space chairs, screen patients, and move carefully through each appointment.

Oncology teams were asked to be flexible, which sometimes meant “please make a miracle out of three nurses, two masks, and a printer that jams when frightened.” Humor helped, but it did not erase the moral weight of working without adequate resources.

5. Inequity Became Impossible to Ignore

COVID-19 did not create health inequity, but it certainly put a spotlight on it. Patients with limited insurance, unstable housing, language barriers, low health literacy, limited broadband access, inflexible jobs, or long travel distances often faced greater disruption. Telemedicine helped many patients, but it also left behind those without devices, privacy, internet access, or digital confidence.

For oncology professionals committed to justice, watching vulnerable patients fall further behind was a source of moral distress. It is painful to know the right thing to do and still lack the tools to do it.

How Moral Injury Showed Up in Oncology Teams

Moral injury rarely walks into clinic wearing a name tag. It may show up as irritability, numbness, insomnia, guilt, cynicism, emotional withdrawal, dread before work, or a sense that the job has become spiritually unsafe. Some clinicians describe replaying decisions long after the shift ends. Others feel anger toward institutions, public policy failures, misinformation, or even patients and families who are also scared.

Oncology professionals may be especially vulnerable because the field already involves grief, uncertainty, and repeated exposure to suffering. Cancer care asks clinicians to form meaningful relationships with patients over months or years. When the pandemic disrupted those relationships, the emotional consequences were not minor.

Common Signs of Moral Injury in Oncology Practice

• Persistent guilt about treatment delays or altered care plans
• Feeling betrayed by leadership, systems, or public health failures
• Loss of trust in institutions or professional purpose
• Emotional numbness after repeated patient losses
• Avoidance of difficult conversations because they feel unbearable
• Anger that seems larger than the immediate situation
• Questioning whether one can continue practicing oncology

COVID-19 Changed the Doctor-Patient Relationship

Oncology communication is usually built on presence: sitting down, reading the room, noticing who is holding whose hand, watching the patient’s face when the scan results are explained. Masks, face shields, distancing, and telehealth changed that. Clinicians had to communicate life-changing news through layers of plastic, glitchy video, or a phone call with three family members talking at once.

Telemedicine was invaluable, especially for follow-up visits, symptom checks, survivorship care, second opinions, and reducing travel burdens. Yet it was not a perfect substitute for every cancer encounter. A new diagnosis, a goals-of-care discussion, a serious progression, or a transition to hospice can feel painfully thin through a screen.

The moral challenge was not whether telehealth was “good” or “bad.” It was deciding when convenience became compromise, and when infection prevention outweighed the healing power of physical presence.

The Role of Leadership in Preventing Moral Injury

Moral injury should not be treated as a personal weakness. Telling clinicians to become more resilient without fixing the conditions that injured them is like handing someone an umbrella while the roof is on fire. Individual coping matters, but systems must carry their share of responsibility.

Oncology leaders can reduce moral injury by being transparent about decisions, including frontline staff in policy changes, explaining the ethical reasoning behind triage plans, providing adequate protective equipment, supporting mental health care, and creating spaces where clinicians can discuss difficult cases without blame.

What Support Actually Looks Like

Support is not a pizza party after a traumatic month, though pizza has its place in civilization. Real support includes protected time for debriefing, access to confidential counseling, peer-support programs, ethics consultation, staffing models that acknowledge human limits, flexible scheduling, bereavement rituals, and leadership that says, “This was not okay, and we are going to change what we can.”

When clinicians feel heard and protected, moral distress may still occur, but it is less likely to harden into moral injury. The difference is not whether painful decisions happen. The difference is whether clinicians are abandoned inside them.

Moral Resilience: Helpful, But Not a Magic Wand

Moral resilience is the capacity to stay connected to one’s values while facing ethical adversity. It can involve reflection, self-compassion, honest conversation, spiritual care, peer support, mindfulness, and the ability to name what happened without drowning in it.

For oncology clinicians, moral resilience might mean acknowledging, “I hate that we delayed this scan, but the decision was made with the patient’s safety and the available evidence in mind.” It might mean discussing a painful case with colleagues instead of carrying it home alone. It might mean apologizing when communication fell short, advocating for better systems, or allowing grief to be grief rather than converting it into productivity by Tuesday.

Still, resilience must not become a shiny word used to excuse broken systems. The goal is not to train clinicians to tolerate the intolerable. The goal is to build oncology practices where ethical care is possible even during crisis.

Lessons for Oncology After COVID-19

Keep the Good Innovations

COVID-19 forced rapid changes that should not all be discarded. Telehealth can improve access when used thoughtfully. Home-based symptom monitoring can help patients avoid unnecessary travel. Oral treatment pathways, local laboratory partnerships, and flexible follow-up models may reduce burdens for selected patients.

The lesson is not to return automatically to 2019 workflows. The lesson is to keep what improved patient-centered care and revise what caused harm.

Prepare Ethical Playbooks Before the Next Crisis

Oncology programs need clear, ethically grounded crisis plans before the next emergency. These plans should address treatment prioritization, communication standards, visitor policies, clinical trial continuity, palliative care access, and equity safeguards. They should also include frontline clinicians, patients, caregivers, ethicists, and community representatives.

When ethical decisions are made in advance with transparency, clinicians are less likely to feel they are improvising alone in the dark.

Make Workforce Well-Being a Quality Metric

Cancer centers measure survival, response rates, infection rates, readmissions, and patient satisfaction. They should also measure workforce well-being, moral distress, turnover risk, and psychological safety. A depleted oncology workforce is not a side issue. It is a patient-care issue.

Clinicians who are supported are better able to communicate, coordinate, notice subtle clinical changes, and stay emotionally present with patients. Healing the healers is not sentimental. It is operationally smart.

Experiences From the Oncology Front Line During COVID-19

The lived experience of practicing oncology during COVID-19 can be understood through the small moments that rarely make it into official reports. Imagine an oncologist sitting with a patient whose lymphoma is responding beautifully, while both are secretly worried that the very infusion saving his life could make him more vulnerable to severe infection. The physician smiles with her eyes because the rest of her face is hidden behind a mask. The patient jokes that he can no longer tell whether anyone is smiling, angry, or just hungry. Everyone laughs for three seconds. Then the room becomes serious again.

Or consider the oncology nurse who has spent years making the infusion suite feel less frightening. Before the pandemic, she might warm a blanket, pull up a chair, ask about grandchildren, and let a spouse sit close. During COVID-19, she became part nurse, part infection-control officer, part emotional translator. She had to enforce distancing rules she did not create. She had to tell family members they could not enter. She had to comfort patients through gloves and masks while moving quickly enough to keep the schedule from collapsing. At the end of the day, she might sit in her car for a few minutes before driving home, not because she was dramatic, but because the human nervous system sometimes needs a lobby between work and life.

Radiation oncology teams had their own version of the burden. Radiation treatment often requires daily visits over several weeks. During a viral surge, every visit raised the same question: how do we maintain a curative treatment schedule while minimizing exposure? Staff screened symptoms, rearranged waiting rooms, adjusted workflows, cleaned surfaces with the dedication of people trying to disinfect the concept of fear itself, and kept patients moving through care. For some patients, the routine was reassuring. For others, each trip felt like walking through a storm to get to a lighthouse.

Surgical oncologists faced the anguish of postponed procedures. A tumor that appeared operable in March might be reevaluated weeks later with new uncertainty. Surgeons are trained to act decisively; waiting can feel like betrayal. Yet operating during severe hospital strain could mean no ICU bed, inadequate postoperative support, or avoidable exposure. The moral injury came from knowing that both action and delay could harm.

Palliative care clinicians also carried a heavy load. They helped patients and families talk about goals, comfort, fear, and death in a period when death had become both more common and more isolated. They arranged video calls, coached families through remote goodbyes, and supported oncology colleagues who were grieving patient after patient. Their work proved that technology can connect people, but it cannot fully replace the weight of a hand held at the bedside.

Clinical trial teams faced another painful reality. Trials are often sources of hope, especially for patients with advanced cancer. COVID-19 disrupted enrollment, monitoring, travel, imaging, and research operations. Some patients lost access to trial options. Staff had to explain delays that felt deeply unfair. Behind every “protocol deviation” was often a person trying very hard to stay alive.

These experiences show why moral injury in oncology was not only about dramatic triage decisions. It was also about repeated smaller wounds: the family member turned away at the door, the delayed scan, the phone call replacing a hug, the patient apologizing for being scared, the clinician saying “we are doing everything we can” while privately knowing that “everything” had been narrowed by circumstances beyond the patient’s control.

Conclusion: Naming the Wound Is the First Step

Moral injury and practicing oncology during COVID-19 are inseparable topics because cancer care is built on moral commitments: relieve suffering, tell the truth, honor dignity, protect the vulnerable, and never treat a person as a diagnosis with shoes. The pandemic made those commitments harder to fulfill. It forced clinicians to make decisions in conditions of uncertainty, scarcity, fear, and grief.

The way forward is not to pretend that oncology teams simply “adapted.” They did adapt, often heroically, but adaptation came at a cost. Cancer centers, hospitals, and professional organizations must treat moral injury as a serious workforce and patient-care issue. That means better crisis planning, stronger ethical support, investment in staffing, attention to equity, and cultures where clinicians can speak honestly about what hurt.

COVID-19 changed oncology, but it also clarified something essential: excellent cancer care depends not only on drugs, scans, and protocols, but on the moral health of the people delivering them. Protecting that moral health is not a luxury. It is part of the treatment plan.